UK markets close in 7 hours 53 minutes

eFFECTOR Therapeutics, Inc. (EFTR)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
0.2800-0.0030 (-1.06%)
At close: 04:00PM EDT
0.3400 +0.06 (+21.43%)
After hours: 07:59PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 1.32M
Enterprise value -3.82M
Trailing P/E 0.84
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)1.59
Enterprise value/revenue N/A
Enterprise value/EBITDA -0.41

Trading information

Stock price history

Beta (5Y monthly) 0.82
52-week change 3-98.52%
S&P500 52-week change 324.96%
52-week high 322.5000
52-week low 30.2540
50-day moving average 31.7267
200-day moving average 39.8293

Share statistics

Avg vol (3-month) 3447.7k
Avg vol (10-day) 3685.2k
Shares outstanding 54.7M
Implied shares outstanding 64.7M
Float 84.58M
% held by insiders 12.91%
% held by institutions 123.71%
Shares short (15 May 2024) 4110.66k
Short ratio (15 May 2024) 40.73
Short % of float (15 May 2024) 42.37%
Short % of shares outstanding (15 May 2024) 42.35%
Shares short (prior month 15 Apr 2024) 4244.03k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 21:25
Last split date 312 Jan 2024

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-83.33%
Return on equity (ttm)N/A

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -32.59M
Net income avi to common (ttm)-34.63M
Diluted EPS (ttm)-12.5700
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)25.38M
Total cash per share (mrq)5.4
Total debt (mrq)20.25M
Total debt/equity (mrq)2,448.37%
Current ratio (mrq)1.03
Book value per share (mrq)0.21

Cash flow statement

Operating cash flow (ttm)-29.19M
Levered free cash flow (ttm)-17.67M